PHARVARIS N.V. EO -12 (9EN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PHARVARIS N.V. EO -12 (9EN) has a cash flow conversion efficiency ratio of -0.140x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-37.95 Million ≈ $-44.37 Million USD) by net assets (€271.27 Million ≈ $317.15 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 9EN stock market capitalisation for the company's overall valuation and market capitalisation.
PHARVARIS N.V. EO -12 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how PHARVARIS N.V. EO -12's cash flow conversion efficiency has evolved over time, based on yearly financial data.
PHARVARIS N.V. EO -12 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PHARVARIS N.V. EO -12 ranked by their cash flow conversion efficiency. See 9EN debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FLEX LNG Ltd
NYSE:FLNG
|
0.014x |
|
Anhui Wanwei Updated High-tech Material Industry Co Ltd
SHG:600063
|
0.005x |
|
Pebblebrook Hotel Trust
NYSE:PEB
|
0.033x |
|
Usha Martin Limited
NSE:USHAMART
|
0.112x |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019
|
0.005x |
|
Molymet
SN:MOLYMET
|
0.314x |
|
China Tianying Inc
SHE:000035
|
0.013x |
|
China Aluminum International Engineering Corp Ltd
SHG:601068
|
0.031x |
Annual Cash Flow Conversion Efficiency for PHARVARIS N.V. EO -12 (2021–2025)
The table below shows the annual cash flow conversion efficiency of PHARVARIS N.V. EO -12 from 2021 to 2025. View PHARVARIS N.V. EO -12 share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €271.27 Million ≈ $317.15 Million |
€-137.07 Million ≈ $-160.25 Million |
-0.505x | -12.63% |
| 2024-12-31 | €267.76 Million ≈ $313.04 Million |
€-120.13 Million ≈ $-140.44 Million |
-0.449x | -85.17% |
| 2023-12-31 | €384.05 Million ≈ $448.99 Million |
€-93.05 Million ≈ $-108.78 Million |
-0.242x | +46.16% |
| 2022-12-31 | €149.26 Million ≈ $174.50 Million |
€-67.16 Million ≈ $-78.52 Million |
-0.450x | -106.78% |
| 2021-12-31 | €204.95 Million ≈ $239.61 Million |
€-44.60 Million ≈ $-52.14 Million |
-0.218x | -- |
About PHARVARIS N.V. EO -12
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and a… Read more